InnoScience (Suzhou) Technology Holding Co., Ltd. Announces Approved H Shares Full Circulation – Major Shareholding Changes

Key Points for Investors

• Hong Kong Stock Exchange has granted listing approval for the full circulation of H Shares for InnoScience (Suzhou) Technology Holding Co., Ltd.
• A total of 373,841,270 Domestic Unlisted Shares will be converted to H Shares, representing approximately 40.85% of the company’s total issued share capital.
• The conversion will involve 35 participating shareholders, including major corporate and individual investors.
• Upon completion, the proportion of H Shares in the company will rise sharply from 57.43% to 98.28%, while Domestic Unlisted Shares will decrease from 42.57% to only 1.72%.

Details of the Conversion and Listing

The company received the listing approval from the Hong Kong Stock Exchange on 14 May 2026 for the conversion and listing of 373,841,270 H Shares. This process covers the full circulation of H Shares, allowing previously unlisted Domestic Shares to become tradable H Shares on the market.

Key participating shareholders and their converted shareholdings include:

• INNOSCIENCE HOLDING PTE. LTD.: 43,001,465 shares (4.70%)
• WEIWEI LUO: 24,604,652 shares (2.69%)
• Jay Hyung Son: 22,818,868 shares (2.49%)
• Suzhou Wujiang Industrial Investment Co., Ltd.: 44,749,893 shares (4.89%)
• Shenzhen CMB Growth No.17 Equity Investment Fund L.P.: 48,902,412 shares (5.34%)
• Several other institutional and venture capital shareholders with significant stakes

The full list of participating shareholders and their respective conversion amounts is extensive, reflecting a broad base of investor participation in the conversion process.

Shareholding Structure Impact

This restructuring marks a significant increase in liquidity and tradability of shares in the Hong Kong market, as the vast majority of the company’s shares will now be H Shares. This could potentially impact the share price due to increased market access and trading volume.

Potential Price-Sensitive Information

• Full circulation of H Shares is a major liquidity event, likely to affect trading dynamics, share price, and investor interest.
• The conversion could attract more international investors and increase the company’s visibility in the market.
• Shareholders are advised to exercise caution, as such structural changes can lead to increased volatility.

Further Steps by the Company

The company will complete the necessary procedures for the conversion of H Shares and will make further announcements regarding the progress of the full circulation and listing process.

The Board is chaired by Dr. Weiwei Luo, with a mix of executive, non-executive, and independent directors overseeing the process.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should exercise caution and consult their financial advisors before making any investment decisions regarding InnoScience (Suzhou) Technology Holding Co., Ltd. The announcement contains inside information that may affect share prices.

InnoScience (Suzhou) Technology Holding Co., Ltd. 全流通H股獲批上市 — 投資者須知

報告重點

• 香港聯交所已批准 InnoScience (Suzhou) Technology Holding Co., Ltd. 全流通H股上市。
• 共373,841,270股境內未上市股份將轉換為H股，佔公司總股本約40.85%。
• 此次轉換涉及35位參與股東，包括多間企業及個人投資者。
• 完成後，公司H股比例將由57.43%大幅提升至98.28%，境內未上市股份則降至僅1.72%。

轉換及上市詳情

公司於2026年5月14日獲香港聯交所批准上市，涉及全流通H股，讓原本未上市的境內股份可於市場交易。

• INNOSCIENCE HOLDING PTE. LTD.：43,001,465股（4.70%）
• 羅偉偉：24,604,652股（2.69%）
• Jay Hyung Son：22,818,868股（2.49%）
• 蘇州吳江產業投資有限公司：44,749,893股（4.89%）
• 深圳招銀成長17號股權投資基金：48,902,412股（5.34%）
• 多家機構及創投股東參與

股權結構變動

此舉大幅提升流動性及股份可交易性，預期將影響股價並提升市場關注度。

潛在價格敏感資訊

• 全流通H股屬重大流動性事件，或影響交易及股價。
• 轉換後有望吸引更多國際投資者，提升公司市場所見度。
• 股東應謹慎操作，結構性改變或帶來波動。

公司後續動作

公司將完成相關轉換程序，並按規定公佈進展。董事會由羅偉偉博士領導，成員包括執行董事、非執行董事及獨立董事。

免責聲明

本文僅供資訊參考，不構成投資建議。投資者應謹慎，並諮詢財務顧問。公告包含或會影響股價之內幕消息。

View INNOSCIENCE Historical chart here